GT200600206A - Nuevos derivados del fluoreno, composiciones que los contienen y su utilizacion - Google Patents

Nuevos derivados del fluoreno, composiciones que los contienen y su utilizacion

Info

Publication number
GT200600206A
GT200600206A GT200600206A GT200600206A GT200600206A GT 200600206 A GT200600206 A GT 200600206A GT 200600206 A GT200600206 A GT 200600206A GT 200600206 A GT200600206 A GT 200600206A GT 200600206 A GT200600206 A GT 200600206A
Authority
GT
Guatemala
Prior art keywords
fluorene
compositions
contain
new derivatives
bencimidazol
Prior art date
Application number
GT200600206A
Other languages
English (en)
Inventor
Patrick Mailliet
Luc Bertin
Fabienne Thompson
Jean-Marie Ruxer
Fabienne Pilorge
Didier Bernard
Herve Minoux
Chantal Carrez
Helene Goulaouic
Thierry Gouyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600206A publication Critical patent/GT200600206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS COMPUESTOS QUÍMICOS, SEGÚN FÓRMULA (I), DERIVADOS DEL FLUORENO Y MÁS PARTICULARMENTE A NUEVOS DERIVADOS DE 4-(BENCIMIDAZOL-2-IL)-FLUORENO O DE 4-(AZABENCIMIDAZOL-2-IL)-FLUORENO, A LAS COMPOSICIONES QUE LOS CONTIENEN, Y A SU UTILIZACIÓN COMO MEDICAMENTOS. MÁS PARTICULARMENTE, LA INVENCIÓN SE REFIERE, SEGÚN UN PRIMER ASPECTO, A NUEVOS DERIVADOS DE 4-(BENCIMIDAZOL-2-IL)-FLUORENO O DE 4-(AZA-BENCIMIDAZOL-2-IL)-FLUORENO QUE PRESENTAN UNA ACTIVIDADA ANTICANCERÍGENA, Y MÁS ESPECIALMENTE, MEDIANTE LA INHIBICIÓN DE LA ACTIVIDAD CATALÍTICA DE TIPO ATPASA DE LA PROTEÍNA CHAPERONA HSP90. T2006
GT200600206A 2005-05-19 2006-05-18 Nuevos derivados del fluoreno, composiciones que los contienen y su utilizacion GT200600206A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0505037A FR2885904B1 (fr) 2005-05-19 2005-05-19 Nouveaux derives du fluorene, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
GT200600206A true GT200600206A (es) 2006-12-26

Family

ID=36036699

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600206A GT200600206A (es) 2005-05-19 2006-05-18 Nuevos derivados del fluoreno, composiciones que los contienen y su utilizacion

Country Status (31)

Country Link
US (1) US7674795B2 (es)
EP (1) EP1888579B1 (es)
JP (1) JP4964874B2 (es)
KR (1) KR101288696B1 (es)
CN (1) CN101203518B (es)
AR (1) AR054125A1 (es)
AT (1) ATE518859T1 (es)
AU (1) AU2006248825B2 (es)
BR (1) BRPI0611424A2 (es)
CA (1) CA2608378C (es)
CR (1) CR9515A (es)
DO (1) DOP2006000112A (es)
EA (1) EA019027B1 (es)
FR (1) FR2885904B1 (es)
GT (1) GT200600206A (es)
HN (1) HN2006018410A (es)
IL (1) IL187163A (es)
JO (1) JO2753B1 (es)
MA (1) MA29493B1 (es)
MX (1) MX2007014443A (es)
MY (1) MY149037A (es)
NO (1) NO20076460L (es)
NZ (1) NZ563239A (es)
PA (1) PA8675701A1 (es)
PE (1) PE20061367A1 (es)
TN (1) TNSN07389A1 (es)
TW (1) TWI386406B (es)
UA (1) UA93203C2 (es)
UY (1) UY29549A1 (es)
WO (1) WO2006123061A2 (es)
ZA (1) ZA200709856B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109160A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
FR2907453B1 (fr) * 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
JP5270571B2 (ja) * 2007-11-22 2013-08-21 出光興産株式会社 有機ｅｌ素子
AU2009233324B2 (en) * 2008-03-31 2015-01-22 Council Of Scientific & Industrial Research Donor-acceptor fluorene scaffolds : a process and uses thereof
GB0809314D0 (en) * 2008-05-22 2008-07-02 Summit Corp Plc Compounds for treating muscular dystrophy
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
FR2932484B1 (fr) * 2008-06-16 2010-06-18 Sanofi Aventis Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2307342B1 (en) 2008-07-02 2017-06-21 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
AR074797A1 (es) 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US9388112B2 (en) 2010-01-06 2016-07-12 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012145330A1 (en) * 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
CN102442973A (zh) * 2011-09-22 2012-05-09 华东理工大学 催化氧化伯醇闭环合成苯并咪唑和苯并噻唑化合物的方法
GB2515909B (en) * 2012-01-31 2020-07-15 Cambridge Display Tech Ltd Composition comprising a fluorescent light-emitting material and triplet-accepting polymer and use thereof
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
AU2013266086B2 (en) 2012-05-25 2018-03-01 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
BR112015022077A2 (pt) 2013-03-15 2017-07-18 Japan Tobacco Inc composto de pirazol-amida e usos medicinais do mesmo
US9173939B2 (en) 2013-05-10 2015-11-03 The University Of British Columbia Ester derivatives of androgen receptor modulators and methods for their use
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
KR20160054523A (ko) 2013-09-09 2016-05-16 브리티쉬 콜롬비아 캔써 에이전시 브랜치 암 영상화 및 치료용 할로겐화 화합물, 및 이들의 사용 방법
KR102280686B1 (ko) 2014-02-11 2021-07-22 삼성전자주식회사 카바졸계 화합물 및 이를 포함한 유기 발광 소자
KR20170002446A (ko) * 2014-04-14 2017-01-06 아비나스 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US10023864B2 (en) 2014-06-06 2018-07-17 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
US11426386B2 (en) 2014-12-05 2022-08-30 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
WO2016090373A1 (en) 2014-12-05 2016-06-09 Case Western Reserve University Compositions and methods of modulating s-nitrosylation
WO2019060720A1 (en) 2017-09-25 2019-03-28 Case Western Reserve University COMPOSITIONS AND METHODS FOR REDUCING SERUM CHOLESTEROL AND PCSK9
WO2016112455A1 (en) 2015-01-13 2016-07-21 British Columbia Cancer Agency Branch Heterocyclic compounds for cancer imaging and treatment and methods for their use
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
JP6873433B2 (ja) * 2015-06-04 2021-05-19 アルヴィナス・オペレーションズ・インコーポレイテッド タンパク質分解のイミド系修飾因子および関連の使用方法
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
WO2018021508A1 (ja) 2016-07-29 2018-02-01 日本たばこ産業株式会社 ピラゾール－アミド化合物の製造方法
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US11931339B2 (en) 2018-06-25 2024-03-19 Case Western Reserve University Compositions and methods for treating tissue injury
JP2022502368A (ja) * 2018-09-21 2022-01-11 ケース ウエスタン リザーブ ユニバーシティ アルドケトレダクターゼ阻害剤およびその使用
CA3115101A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN109574917B (zh) * 2018-12-03 2020-12-08 武汉尚赛光电科技有限公司 一种芴酮衍生物及其制备和应用
KR20210117261A (ko) 2018-12-31 2021-09-28 바이오메아 퓨전, 인크. 메닌-mll 상호작용의 비가역적 억제제
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN110981795B (zh) * 2019-12-18 2021-02-12 武汉世纪久海检测技术有限公司 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法
EP4135675A4 (en) 2020-04-17 2024-04-10 Essa Pharma, Inc. SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6015796A (en) * 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
ES2261463T3 (es) * 2000-08-14 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
EP1456180B1 (en) * 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
EP1572682A4 (en) * 2002-12-20 2008-01-23 Pharmacia Corp ACYCLIC PYRAZOLE COMPOUNDS
US7189723B2 (en) * 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
JP4921162B2 (ja) 2003-02-11 2012-04-25 ヴァーナリス（ケンブリッジ）リミテッド 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
AU2004251949B2 (en) 2003-06-27 2009-05-07 Kyowa Hakko Kirin Co., Ltd. Hsp90 family protein inhibitors
AU2004268820B2 (en) 2003-08-29 2011-07-21 Cancer Research Technology Ltd Pyrimidothiophene compounds
GB0323810D0 (en) * 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
EP1704856A4 (en) * 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90

Also Published As

Publication number Publication date
CA2608378C (fr) 2013-12-31
MX2007014443A (es) 2008-02-11
DOP2006000112A (es) 2007-01-31
TNSN07389A1 (en) 2009-03-17
TW200716633A (en) 2007-05-01
EA200702531A1 (ru) 2008-04-28
EP1888579B1 (fr) 2011-08-03
PE20061367A1 (es) 2007-01-08
AU2006248825A1 (en) 2006-11-23
CN101203518B (zh) 2013-07-24
CR9515A (es) 2008-02-21
JP4964874B2 (ja) 2012-07-04
CA2608378A1 (fr) 2006-11-23
BRPI0611424A2 (pt) 2010-09-08
US7674795B2 (en) 2010-03-09
FR2885904B1 (fr) 2007-07-06
EP1888579A2 (fr) 2008-02-20
MA29493B1 (fr) 2008-05-02
NZ563239A (en) 2011-01-28
WO2006123061A3 (fr) 2007-01-11
JP2008540620A (ja) 2008-11-20
US20080153837A1 (en) 2008-06-26
HN2006018410A (es) 2010-03-05
ATE518859T1 (de) 2011-08-15
PA8675701A1 (es) 2006-12-07
UA93203C2 (ru) 2011-01-25
JO2753B1 (en) 2014-03-15
IL187163A (en) 2014-07-31
AU2006248825B2 (en) 2012-02-23
ZA200709856B (en) 2009-12-30
IL187163A0 (en) 2008-02-09
CN101203518A (zh) 2008-06-18
NO20076460L (no) 2008-02-19
FR2885904A1 (fr) 2006-11-24
KR101288696B1 (ko) 2013-07-22
MY149037A (en) 2013-07-15
KR20080025375A (ko) 2008-03-20
EA019027B1 (ru) 2013-12-30
WO2006123061A2 (fr) 2006-11-23
AR054125A1 (es) 2007-06-06
UY29549A1 (es) 2006-12-29
TWI386406B (zh) 2013-02-21

Similar Documents

Publication Publication Date Title
GT200600206A (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilizacion
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
CR9664A (es) Inhibidores de histona deacetilasa
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CO6511251A2 (es) Compuestos quimicos
SV2007002007A (es) Compuestos de quinolina sustituidos ref. pc 25932a
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
EA200702058A1 (ru) Новые фармацевтические соединения
UY29617A1 (es) Compuestos químicos vii
UY29607A1 (es) Compuestos quimicos
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
BRPI0512843A (pt) inibidores de quinolina
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
PA8579901A1 (es) Bifenilcarboxamidas sustituidas con n-aril piperidina
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina